Medicus Pharma Ltd.
Research Medicus Pharma Ltd. (MDCX) on Bullrun: market cap USD 195.55M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMDCX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Market capUSD 195.55M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 11.62M
- Free cash flow-USD 6.98M
Valuation Snapshot
latest market cap is USD 195.55M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 35.44M | -USD 22.78M | n/a | -2.74 | USD 8.71M | USD 5.48M | -USD 67.55K |
| FY2024 | USD 0 | -USD 11.16M | -USD 10.25M | n/a | -1.16 | USD 4.16M | USD 322.27K | USD 3.13M |
| FY2023 | USD 0 | -USD 5.31M | -USD 4.16M | n/a | -1.53 | USD 1.72M | USD 0 | USD 1.11M |
| FY2022 | USD 0 | -USD 1.69M | -USD 1.06M | n/a | -0.88 | USD 267.65K | USD 1.53M | -USD 12.20M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | USD 195.55M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.93B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.44B | n/a | n/a | n/a |
About Medicus Pharma Ltd.
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Medicus Pharma Ltd.'s market cap?
Medicus Pharma Ltd.'s market capitalization is USD 195.55M.
What does Medicus Pharma Ltd. do?
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023.